StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Free Report) in a research report report published on Sunday morning. The firm issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Price Performance
Shares of BTX traded up $0.05 during mid-day trading on Friday, reaching $6.31. 596,683 shares of the company's stock traded hands, compared to its average volume of 818,761. The stock's 50-day moving average is $3.99 and its two-hundred day moving average is $1.88. Brooklyn ImmunoTherapeutics has a 12 month low of $6.06 and a 12 month high of $8.31. The stock has a market cap of $371.19 million, a P/E ratio of -2.78 and a beta of 4.61.
Brooklyn ImmunoTherapeutics Announces Dividend
The business also recently announced a monthly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, March 14th were given a dividend of $0.0862 per share. This represents a $1.03 dividend on an annualized basis and a dividend yield of 16.38%. The ex-dividend date of this dividend was Friday, March 14th. Brooklyn ImmunoTherapeutics's dividend payout ratio (DPR) is presently -38.33%.
About Brooklyn ImmunoTherapeutics
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Featured Articles
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
